NYSE:DVA - Davita Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$55.00 +1.29 (+2.40 %)
(As of 03/22/2019 06:14 AM ET)
Previous Close$53.71
Today's Range$53.78 - $55.67
52-Week Range$48.25 - $79.11
Volume2.28 million shs
Average Volume2.09 million shs
Market Capitalization$9.15 billion
P/E Ratio15.41
Dividend YieldN/A
Beta1.3
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2018, it provided dialysis and administrative services in the United States through a network of 2,664 outpatient dialysis centers serving approximately 202,700 patients; and operated 241 outpatient dialysis centers located in 9 countries outside of the United States serving approximately 25,000 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

Receive DVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
CUSIP23918K10
Phone720-631-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.40 billion
Cash Flow$7.4425 per share
Book Value$23.55 per share

Profitability

Net Income$159.39 million

Miscellaneous

Employees77,700
Market Cap$9.15 billion
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Davita (NYSE:DVA) Frequently Asked Questions

What is Davita's stock symbol?

Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

How will Davita's stock buyback program work?

Davita declared that its Board of Directors has initiated a share buyback plan on Wednesday, October 11th 2017, which authorizes the company to repurchase $1,500,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

How were Davita's earnings last quarter?

Davita Inc (NYSE:DVA) announced its earnings results on Wednesday, February, 13th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.89 by $0.01. The company earned $2.82 billion during the quarter, compared to the consensus estimate of $2.97 billion. Davita had a net margin of 1.40% and a return on equity of 14.17%. The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.92 EPS. View Davita's Earnings History.

When is Davita's next earnings date?

Davita is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Davita.

What price target have analysts set for DVA?

9 Wall Street analysts have issued 12-month price objectives for Davita's shares. Their predictions range from $59.00 to $70.00. On average, they expect Davita's share price to reach $64.5733 in the next year. This suggests a possible upside of 17.4% from the stock's current price. View Analyst Price Targets for Davita.

What is the consensus analysts' recommendation for Davita?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Davita.

Has Davita been receiving favorable news coverage?

News articles about DVA stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Davita earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the immediate future.

Who are some of Davita's key competitors?

What other stocks do shareholders of Davita own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Davita investors own include Gilead Sciences (GILD), Celgene (CELG), CA (CA), BlackRock (BLK), Wells Fargo & Co (WFC), Home Depot (HD), General Electric (GE), Nike (NKE), Walt Disney (DIS) and Mastercard (MA).

Who are Davita's key executives?

Davita's management team includes the folowing people:
  • Mr. Kent J. Thiry, Chairman & CEO (Age 63)
  • Mr. Joel Ackerman, Chief Financial Officer (Age 54)
  • Mr. James K. Hilger, Chief Accounting Officer (Age 57)
  • Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 51)
  • Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 48)

Who are Davita's major shareholders?

Davita's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.79%), Norges Bank (3.22%), Dimensional Fund Advisors LP (1.55%), Gates Capital Management Inc. (1.34%), FMR LLC (1.22%) and Oregon Public Employees Retirement Fund (1.13%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.

Which major investors are selling Davita stock?

DVA stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, Partner Fund Management L.P., Consulta Ltd, Bank of New York Mellon Corp, Manning & Napier Group LLC, Two Sigma Investments LP and KBC Group NV. Company insiders that have sold Davita company stock in the last year include Charles Berg, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita.

Which major investors are buying Davita stock?

DVA stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Oregon Public Employees Retirement Fund, DPM Capital LLC, Caption Management LLC, Gates Capital Management Inc., Toronto Dominion Bank and First Trust Advisors LP. View Insider Buying and Selling for Davita.

How do I buy shares of Davita?

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Davita's stock price today?

One share of DVA stock can currently be purchased for approximately $55.00.

How big of a company is Davita?

Davita has a market capitalization of $9.15 billion and generates $11.40 billion in revenue each year. The company earns $159.39 million in net income (profit) each year or $3.57 on an earnings per share basis. Davita employs 77,700 workers across the globe.

What is Davita's official website?

The official website for Davita is http://www.davita.com.

How can I contact Davita?

Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected]


MarketBeat Community Rating for Davita (NYSE DVA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  428 (Vote Underperform)
Total Votes:  820
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel